Skip to search formSkip to main contentSkip to account menu

7-ethyl-10-hydroxycamptothecin glucuronide

Known as: SN-38 glucuronide 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
PURPOSE We aim to identify genetic variation, in addition to the UGT1A1*28 polymorphism, that can explain the variability in… 
Highly Cited
2006
Highly Cited
2006
Pharmacogenetic testing for UDP‐glucuronosyltransferase (UGT) 1A1*28, a promoter variant of the UGT1A1 gene, is now carried out… 
Highly Cited
2002
Highly Cited
2002
The metabolism of irinotecan (CPT-11) involves sequential activation to SN-38 and detoxification to the pharmacologically… 
Highly Cited
2002
Highly Cited
2002
Abstract.Purpose: The extensive and unpredictable biliary excretion of CPT-11 and its metabolites, SN-38 and SN-38 glucuronide… 
Highly Cited
2002
Highly Cited
2002
Irinotecan hydrochloride (CPT-11) is an anticancer agent with unpredictable bouts of diarrhea as a dose-limiting toxic side… 
Highly Cited
2000
Highly Cited
2000
This study determined the disposition of irinotecan hydrochloride trihydrate (CPT-11) after i.v. infusion of 125 mg/m(2) (100… 
Highly Cited
1999
Highly Cited
1999
PURPOSE To determine the activity, toxicity, and pharmacokinetics of irinotecan (CPT-11, Camptosar; Pharmacia & Upjohn, Kalamazoo… 
Highly Cited
1998
Highly Cited
1998
PURPOSE In vitro synergy between cisplatin and irinotecan (CPT-11) has been reported. We designed a combination schedule of these… 
Highly Cited
1996
Highly Cited
1996
PURPOSE A pharmacokinetic study was performed during a phase II clinical trial of irinotecan (CPT-11) to confirm the…